Biotechnology company developing therapies for neurodegenerative diseases, with a focus on GBA-associated parkinsonism
Biotechnology company developing therapies for neurodegenerative diseases, with a focus on GBA-associated parkinsonism. Its lead drug candidate, LTI-291, targets disease biology linked to GBA1 mutations and lysosomal function; the company also researches other lysosomal enzyme deficiencies.